Pfizer CentreOne

SIDE BY SIDE

ISSUE 01 JANUARY 2021

IN THIS ISSUE:

Welcome

Dear Partners,

By any measure, 2020 was a very difficult year. Covid-19 claimed the lives of more than a million people worldwide. National shutdowns brought job losses, business closures, and furthered existing social disparities. Lack of childcare options and the transition to remote learning prompted many women to exit the workforce, potentially reversing decades of progress in gender equality. The inability to see loved ones and participate in communal events made people feel isolated. All of us can probably add our personal stories to the long list of challenges that the passing year has posed.

But 2020 also brought us a lot to be proud of. It showed the strength and resilience of humanity, from the heroic actions of frontline health workers and dedication of educators, to communities coming together to help their most vulnerable members. As a Pfizer colleague, I am incredibly proud of our organization's work to develop a Covid-19 vaccine under accelerated timelines and of the ongoing efforts to make the vaccine available to the world's population. Pfizer CentreOne provided API and manufactured Covid-19 treatments for other pharmaceutical companies, as many successful partnerships were forged during the pandemic. We can all take pride in similar moments of courage and collaboration in our organizations.

As I reflect on 2020, I'd like to express my deepest gratitude to all of you. At Pfizer CentreOne, we are proud of the trust you placed in our organization, whether it's for securing your API or intermediates supply, or developing and commercializing your products. Together with you, we drew inspiration from our purpose to help patients in need, and that has never been more important than it is now. I'd like to recognize our teams for their dedication and hard work, despite the significant personal challenges posed by the pandemic. Special recognition goes to Pfizer Global Supply partners whose efforts to secure uninterrupted supply of medicines have been truly heroic.

We typically have multiple opportunities to meet each other throughout a year. 2020 brought in-person events to an abrupt halt, yet we managed to stay connected. Many of you joined Pfizer CentreOne's first virtual event, Delivering in Oral Solids, and found this new way of learning about our business helpful. Some joined our virtual due diligence tours which brought our sites directly to you. This customer newsletter is a first for us as well, and we hope that you find it informative. Staying in close touch with our partners is important to us and we are committed to doing so in engaging and fresh ways.

As we begin 2021, I am inspired by the possibilities. My hope is that we will continue to work with greater agility and focus, expand industry partnerships, and accelerate the timelines for developing cures for the world's most significant diseases. Our business will continue to focus on our core platforms – supplying high quality APIs and intermediates, and delivering development, manufacturing, and regulatory expertise in small molecule API, large molecule biologics, oral solids, and sterile injectables. We will also continue to expand access for our customers. One example is our newly constructed biotechnology center in Hangzhou, China that facilitates entry into this important market. Together with commercial developments, we will be focused on delivering outstanding customer experience and fulfilling our promise of being the Partner of Choice.

As you reflect on this challenging year, I hope you feel as much pride as I do for everything that we've accomplished together. I'd also like to wish you and your families good health for the year ahead.

I look forward to growing our partnership in the future.

Yours,



We asked Pfizer CentreOne colleagues to describe the impact our organization had in 2020 with one word. Here are their responses.

Andrew Moore

Andrew Moore assumed the role of General Manager of Pfizer CentreOne in August 2020. Andrew is an experienced healthcare leader, innovator and entrepreneur who began his healthcare career in sales and marketing, including seven years at Pfizer. He has also held leadership roles at AmerisourceBergen and McKesson. Most recently Andrew was the CEO of CogxVision, a Carnegie Mellon University start-up that applies artificial intelligence and machine learning to improve outcomes for the healthcare industry.

Prior to his professional career, Andrew served in the U.S. Army where he received multiple accolades, including the Bronze Star for his combat experience in Iraq Desert Storm. Andrew holds an undergraduate degree from University of Southern Mississippi and participated in a MSBA graduate candidate degree program at Boston University in Heidelberg, Germany.

Connect with Andrew on LinkedIn

COURAGE IN ACTION:

Pfizer CentreOne's Covid-19 Task Force

Pfizer's response to Covid-19 is well-known. Less known is the role that Pfizer CentreOne played in responding to the pandemic. We would like to recognize the colleagues who showed courage and excellence in responding to the unprecedented surge in demand for manufacturing. Their work resulted in the delivery of critical medicines to patients in need and advanced progress in the prevention and treatment of the virus.

> "At Pfizer we're promising to use any of our excess manufacturing capacity, and potentially shift our production, to support others in getting their lifesaving breakthroughs into the hands of patients as quickly as possible."

This portion of Pfizer's 5-Point Covid-19 plan, introduced by Pfizer's CEO Albert Bourla in March 2020, prompted an increase in demand for Pfizer CentreOne's manufacturing capabilities. We received numerous requests through different channels from existing and new customers for molecular entities that showed potential for treating Covid-19 symptoms or for Covid-19 prophylactics. In the face of this unprecedented demand the company formed a task force to ensure all incoming requests could be correctly categorized and responded to within just seven days. Over the course of several months, the task force fielded more than fifty inquiries, which led to positive resolutions for new and existing partners.

Meeting critical demand

The operations team had the challenge of opening capacity within Pfizer CentreOne's manufacturing network to meet these new critical demands. Schedules were revised to prioritize Covid-19 medicines, with both sterile injectable and oral solid dose lines running on adapted schedules. Our teams met more frequently to manage the line capacity changes and a Covid-19 specific tracker was utilized and reviewed daily to ensure all customer requests were addressed. Equally important was maintaining the safety of Pfizer colleagues. Our manufacturing colleagues based onsite implemented social distancing and screening policies, while others adapted to working remotely.

Balancing the need to ensure ongoing availability of existing medicines while also meeting demand for Covid-related products relied on efficient organization, process excellence and multi-team collaboration. Pfizer CentreOne was able to pivot effectively and rearrange schedules and priorities within its facilities at short notice.

The spirit of collaboration

One example of how we leveraged the expertise of our cross-functional teams to find a novel solution is the delivery of an anti-viral product for compassionate use to patients in China. In less than two months, the team gained the approvals, facilitated the unique packaging process, acquired all necessary importation paperwork, and aligned with Supply Chain/Logistics to ensure SAP readiness.

Another notable example of our Covid-19 response is the multi-year agreement with Gilead Sciences, Inc. to manufacture and supply Gilead's investigational antiviral remdesivir, at our McPherson, Kansas facility.

"From the beginning it was clear that no one company or innovation would be able to bring an end to the Covid-19 crisis. Pfizer's agreement with Gilead is an excellent example of members of the innovation ecosystem working together to deliver medical solutions," said Albert Bourla. "Together, we are more powerful than alone. As one of the largest manufacturers of vaccines, biologics and sterile injectables, it is a privilege to offer our expertise and infrastructure to help fight this pandemic. In that spirit, we are pleased that Gilead is using our manufacturing capacity to help facilitate supply of this medicine to patients as quickly as possible."

Patients first

We have helped customers to supply patients in need of antibiotics, analgesics, anesthetics, and immuno-suppressants, just to name a few. We also answered the call to produce more API needed for clinical trials. We facilitated supply of a Pfizer antibiotic to an external customer in Italy, provided quotes for APIs to new customers, and answered RFPs for new therapies to fight viral and bacterial infections. Ultimately, Pfizer CentreOne's pandemic response was about the patients. With a clear organizational structure and high-quality internal processes, the team was able to assemble quickly, review issues and propose solutions to ensure patients received the treatments they needed.

More information on Pfizer's Covid-19 response **here**

> "Together, we are more powerful than alone.
>
> **Albert Bourla, CEO of Pfizer**

Pfizer CentreOne's Manufacturing, At Your Fingertips: Due Diligence Tours Go Virtual

A due diligence visit is a key milestone for prospective customers of Pfizer CentreOne. It offers an opportunity to see the site's laboratories, manufacturing areas, and warehouses, go deeper into the proposed process and meet the project team. The pandemic restricted site access across most of the globe and placed due diligence visits on an indefinite hold.

Mission impossible? Not for Pfizer CentreOne! We partnered with Pfizer Digital, the team driving digital innovation, to recreate the experience of touring the site with 3D scanning technology. We dispatched 3D cameras to the sites to capture their spaces and equipment. The resulting scans or virtual twins provide a first-person experience of walking through the facility with the ability to zoom in on the points of interest. The technology also allows customers to access parts of the site that typically wouldn't be open for visitors, such as high containment areas. The site experts guide the virtual tour and answer any questions that might arise.

The feedback exceeded our expectations. Our customers enjoyed the convenience of touring the site from their homes, combined with the ability to go in-depth on any part of the development or manufacturing process. "The experience is so real you forget you are not onsite," said one of the recent digital visitors.

Pfizer CentreOne's plans include a comprehensive map of the entire manufacturing network, where a user can view any of our sites and explore their capabilities. While it's still unclear whether virtual tours could completely replace the in-person experience, they certainly demonstrate our ability to use the latest technology to meet the needs of our customers.

Pfizer CentreOne paints a new picture with ‘Experience the Art of Science’ campaign

We caught up with our Global Customer Acquisition Marketing Lead, Christine Loria, to find out more about ‘Experience the Art of Science’, Pfizer CentreOne’s new development services marketing campaign.

Q: Please tell us about the origin of the campaign.

A: We wanted to bring attention to Pfizer CentreOne’s development services as we know that there are many small and medium biotechs out there that share our purpose of delivering breakthroughs for patients.

We offer drug development and optimization capabilities including formulation, clinical drug manufacturing, analytical testing, validation and method development across small molecule APIs, large molecule biologics, oral solids and sterile injectables. Working with Pfizer CentreOne means access to incredible scientific expertise and a team of creative collaborators and we wanted to bring this to life in our marketing.

Q: What inspired the campaign’s bold look and feel?

A: Our inspiration for this campaign came from speaking to customers and hearing how Pfizer CentreOne has helped them with their projects. This included addressing complex scientific challenges in a creative and unique way where one customer compared the process to composing music together at the piano!

The campaign theme, ‘Experience the Art of Science’, focuses on the creative thinking and novel approaches that go into our development services work. We’ve looked to bring this to life visually using macro shots of real scientific images from our team that have been magnified and, in some cases, layered with brand colors, to look like abstract art.

Q: How is this campaign unique?

A: The campaign uses images taken by our Pfizer colleagues and it’s a fun and different way of showcasing our talent and the work we do. Being able to feature Pfizer colleagues and our work as a piece of art brings a new dynamic to the conversation and is a unique approach to promoting our services.

Q: What would you like your customers to know with this campaign?

A: Experience the art of science is all about seeing how we can help you if you have a project challenge. We have the scientific expertise to support you throughout your drug development journey and we’ll do it in a collaborative way.

Q: When and how will this campaign come to life?

A: The campaign launched in early December 2020 and will be featured on our LinkedIn channel as well as various media platforms in the development space. Keep a look out and let us know what you think!



IMAGE

Scanning electron micrograph for Irinotecan Hydrochloride
James Whybrow, Materials Characterisation, Sandwich, UK.

Introducing Pfizer CentreOne's Regulatory Affairs Team

Chris Rojewski, Associate Director of Regulatory Affairs, reflects on what motivates his team to deliver.

Pfizer CentreOne's Regulatory Affairs team was recently honored as a finalist of the 17th Annual CPhI Pharma Awards in the category "Excellence in Pharma: Regulatory Procedures and Compliance." We caught up with Chris Rojewski, Associate Director of Regulatory Affairs, to get his take on what motivates his team to deliver.

"Within the Regulatory Affairs team, our intention is to provide customers with a regulatory application that contains everything regulators are looking for to achieve a first pass approval. We do this by working with our technical experts and utilizing their knowledge to build documents that address the criteria from regulators. This takes the burden off our customers - we are their trusted partner and want to see them succeed, so we strive to provide the best regulatory application we can."

"We want to get our customers across the finish line, as the medications and therapies we help them manufacture will ultimately have a positive impact on patients' lives. Seeing clients achieve this with our support brings us a lot of joy and makes it all worthwhile."

At Pfizer CentreOne, we have two Regulatory Affairs sub-teams with knowledgeable and experienced professionals who are instrumental in the drug approval process. One of the teams is dedicated to commercially available APIs and intermediates; the other team supports small and large molecule API and drug products.

For sale APIs and pharmaceutical intermediates support:

- Submission and maintenance of Drug Master Files (DMFs)
- Providing new or updated DMF letters of access to customers
- Responding to questions from regulatory authorities
- Negotiating specifications
- Providing open files to customers upon request
- Assessing CMC changes
- Informing customers of DMF amendments
- Notifying customers of any quality issues
- Preparation of country-specific documents
- Updating older DMFs to today's standards

Small & large molecule API and drug products support:

- Early stage regulatory strategic planning
- Managing regulatory submissions (e.g. authoring of eCTD sections)
- Responding to questions from regulatory authorities
- Labeling support
- Assessing CMC changes
- Notifying customers of CMC changes requiring submission
- Post-approval submission support
- Support for geo-expansion projects

Pfizer CentreOne

SIDE BY SIDE

Let's collaborate

pfizercentreone@pfizer.com
pfizercentreone.com



IMAGE

Two polymorphs of cholesteryl acetate recrystallised from the melt
Gary Nichols, Materials Characterisation, Sandwich, UK.